JP4878436B2 - 抗不安剤 - Google Patents
抗不安剤 Download PDFInfo
- Publication number
- JP4878436B2 JP4878436B2 JP2005029114A JP2005029114A JP4878436B2 JP 4878436 B2 JP4878436 B2 JP 4878436B2 JP 2005029114 A JP2005029114 A JP 2005029114A JP 2005029114 A JP2005029114 A JP 2005029114A JP 4878436 B2 JP4878436 B2 JP 4878436B2
- Authority
- JP
- Japan
- Prior art keywords
- serine
- phosphatidylserine
- cysteine
- chicks
- anxiolytic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002249 anxiolytic agent Substances 0.000 title claims description 22
- 230000000949 anxiolytic effect Effects 0.000 title claims description 16
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 91
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 49
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims description 33
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 claims description 30
- 229950006137 dexfosfoserine Drugs 0.000 claims description 30
- JJIHLJJYMXLCOY-BYPYZUCNSA-N N-acetyl-L-serine Chemical compound CC(=O)N[C@@H](CO)C(O)=O JJIHLJJYMXLCOY-BYPYZUCNSA-N 0.000 claims description 22
- 241001465754 Metazoa Species 0.000 claims description 19
- 239000000126 substance Substances 0.000 claims description 19
- 208000019901 Anxiety disease Diseases 0.000 claims description 17
- 230000036506 anxiety Effects 0.000 claims description 17
- 238000000605 extraction Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 238000000746 purification Methods 0.000 claims description 11
- 238000003786 synthesis reaction Methods 0.000 claims description 10
- 238000006911 enzymatic reaction Methods 0.000 claims description 7
- 230000007065 protein hydrolysis Effects 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 70
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 66
- 229960001153 serine Drugs 0.000 description 65
- 235000004400 serine Nutrition 0.000 description 48
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 34
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 27
- 238000012360 testing method Methods 0.000 description 26
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 25
- 235000018417 cysteine Nutrition 0.000 description 25
- ZPDQFUYPBVXUKS-YADHBBJMSA-N 1-stearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OC[C@H](N)C(O)=O ZPDQFUYPBVXUKS-YADHBBJMSA-N 0.000 description 24
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 23
- 150000001875 compounds Chemical class 0.000 description 21
- 239000004471 Glycine Substances 0.000 description 17
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 16
- 230000002269 spontaneous effect Effects 0.000 description 16
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 15
- 235000013305 food Nutrition 0.000 description 15
- 230000033001 locomotion Effects 0.000 description 15
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 15
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 9
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 8
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 235000010469 Glycine max Nutrition 0.000 description 6
- 244000068988 Glycine max Species 0.000 description 6
- 230000003542 behavioural effect Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 235000013376 functional food Nutrition 0.000 description 6
- 235000013402 health food Nutrition 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 5
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 5
- 230000000049 anti-anxiety effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- GICLSALZHXCILJ-UHFFFAOYSA-N ctk5a5089 Chemical compound NCC(O)=O.NCC(O)=O GICLSALZHXCILJ-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000006742 locomotor activity Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- YVOOPGWEIRIUOX-BXRBKJIMSA-N (2r)-2-azanyl-3-sulfanyl-propanoic acid Chemical compound SC[C@H](N)C(O)=O.SC[C@H](N)C(O)=O YVOOPGWEIRIUOX-BXRBKJIMSA-N 0.000 description 4
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 235000013330 chicken meat Nutrition 0.000 description 4
- 229960003699 evans blue Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 244000144972 livestock Species 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 150000003354 serine derivatives Chemical class 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 102100027992 Casein kinase II subunit beta Human genes 0.000 description 3
- 101710158100 Casein kinase II subunit beta Proteins 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000012343 cottonseed oil Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013345 egg yolk Nutrition 0.000 description 3
- 210000002969 egg yolk Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 235000014102 seafood Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 2
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010013296 Sericins Proteins 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 230000000508 neurotrophic effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 125000001095 phosphatidyl group Chemical group 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 150000003408 sphingolipids Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- -1 thienodiazepines Chemical class 0.000 description 2
- 238000006276 transfer reaction Methods 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108010022355 Fibroins Proteins 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004665 fatty acids Chemical group 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- JZRYQZJSTWVBBD-UHFFFAOYSA-N pentaporphyrin i Chemical compound N1C(C=C2NC(=CC3=NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 JZRYQZJSTWVBBD-UHFFFAOYSA-N 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 125000005539 phosphatidic acid group Chemical group 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 210000000449 purkinje cell Anatomy 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 150000003355 serines Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Description
(非特許文献1:Furuya S. et al, Brain Res. Protoc., 3, 192, 1998;
非特許文献2:Mitoma, M. et al. Neurosei. Res., 30, 195, 1998;
非特許文献3:Furuya, S. et al. Proc. Natl. Acad. Sci. USA, 97, 11528, 2000;
非特許文献4:Yamasaki M. et al, J. Neurosci. Res., 21, 7691, 2001)。
Furuya S. et al, Brain Res. Protoc., 3, 192, 1998 Mitoma, M. et al. Neurosei. Res., 30, 195, 1998 Furuya, S. et al. Proc. Natl. Acad. Sci. USA, 97, 11528, 2000 Yamasaki M. et al, J. Neurosci. Res., 21, 7691, 2001 Mitoma, M. et al. J. Biol. Chem., 273, 19363, 1998 Bruni A. et al. Nature, 260, 331, 1976 Amaducci T. et al. Psychopharmacol. Bull., 24, 130, 1988 Crook T. et al. Neurology, 41, 644, 1991 Heywood R. et al. Clin. Trials., 24, 25, 1987
1.セリン、ホスホセリン、アセチルセリンから選択される物質を有効成分とすることを特徴とする抗不安剤。
2.ホスホセリン又はアセチルセリンが蛋白質加水分解法、化学合成法、酵素法、又は動物、植物などから抽出・精製のいずれかの方法によって製造されたものであることを特徴とする1.記載の抗不安剤。
3.セリン、ホスホセリン、アセチルセリンの含有量が5質量%以上であることを特徴とする1.又は2.に記載の抗不安剤。
2.本発明により副作用を起こさず安全な抗不安剤を提供することができる。
3.人以外に家畜、ペットを対象とすることができる。
本発明でいうセリンユニット(Serine Unit)とは、次の一般式1に示される(Serine Unit)「−O−CH(NH2)COOH」をいう。
このセリンユニットを有する化合物としては、セリン(Serine(Ser.))、ホスファチジルセリン(Phosphatidyl-Serine(PS))、ホスホセリン(Phospho-Serine(Phos-S))、アセチルセリン(Acetyl-Serine(Ace-S))、リゾホスファチジルセリン(Lyso Phosphatidyl Serine(Lyso-PS) )を挙げることができる。このセリンユニット(Serine Unit)に接続するR基が、リン酸基である場合は、より強い活性が得られる。
図22はL-セリン(L-Serine(Ser.))、図23はL-アセチルセリン(L-Acetyl-Serine(Ace-S))、図24はO−ホスホセリン(O-Phospho-Serine(Phos-S))、図25はホスファチジルセリン(Phosphatidyl-Serine(PS))、図26はリゾホスファチジルセリン(Lyso Phosphatidyl Serine(Lyso-PS) )、図27はL-システイン(L-Cysteine)、図28はグリシン(Glycine)、図29はホスファチジン酸(Phosphatidic Acid(PA))である。
システイン(Cysteine)は、化学式「H−S−CH(NH2)COOH」で示される。セリンユニットの「−O−」が属性の近い「−S−」に置換されて、その活性が維持されている。
以下に実施例を挙げて本発明を具体的に説明するが、本発明はこれらに限定されるものではない。
試験条件1は、実施例1〜3に適用する。
試験動物:卵用種雄ニワトリヒナ(Julia、4又は5日齢)を試験に使用した。試料を投与する前に、試験動物は体重に応じて群分けを行い、6羽を一組にした。
飼育条件:29±1℃の条件下で、市販飼料(豊橋飼料社製、AX)と水を自由摂食させた。
試験試料:次の試薬はそれぞれ0.1%のエバンスブルーを含むTris-HCl Buffer中に懸濁し、調製した。
大豆由来のホスファチジルセリン(SIGMA、98%、牛脳由来)
ホスファチジルコリン(SIGMA、99%、大豆由来)
ホスファチジルエタノールアミン(SIGMA、98%、牛脳由来)、
L−セリン(和光純薬工業、99%)
試験方法: マイクロシリンジを用いて210mmolの試験試料をニワトリヒナの脳室に投与した。
また、Control群には0.1%のエバンスブルーを含むTris-HCl Bufferを10μl脳室投与した。
行動観察:投与から10分後、各ニワトリヒナを群飼育ケージから行動観察用分離飼育ケージに移し、ニワトリヒナの鳴き回数と自発運動量を記録した。
血液測定:行動観察が終了したニワトリヒナから直ちに採血を行い、血漿中のコルチコステロン濃度をコルチステロンキット(SCETI社製、Rat Corticosterone RIA Kit)で測定した。
また、鳴き回数を測定する間のニワトリヒナの動きを自発運動量として記録し、そのカウントした結果は図3、図4に示した。
これらの結果からセリン(Ser.)とホスファチジルセリン(PS)は、不安によるニワトリヒナの鳴き回数と自発運動量を共に有意に抑えたことが示された。一方、ホスファチジルコリン(PC)にはこの様な結果が示されなかった。
この結果からホスファチジルセリンとセリンは、不安による血中コルチコステロン濃度の上昇を抑え、正常時のレベル近くまで回復する傾向が示された。一方、ホスファチジルコリンにはこの様な結果が示されなかった。
図6〜9に示したように、ホスファチジルセリン(PS)は実施例1と同様な抗不安効果を示したのに対して、セリンユニットを持っていないホスファチジルエタノールアミン(PE)は全くこの様な結果を示さなかった。
以下に追加実施例を挙げて本発明を具体的に説明するが、本発明はこれらに限定されるものではない。
試験条件2は、実施例4〜6に適用する。各実施例は、時期と化合物を変えて実験を行った。
試験動物:卵用種雄ニワトリヒナ(Julia、5又は6日齢)を試験に使用した。試料を投与する前に、試験動物は体重を応じて群分けを行い、7〜9羽を一組にして、化合物数に相当する組数を用いた。
飼育条件:29±1℃の条件下で、市販飼料(豊橋飼料社製、AX)と水を自由摂食させた。
試験試料:次の試薬はそれぞれ0.1%のエバンスブルーを含む0.85%の生理食塩水に溶かし、調製した。
L−セリン(和光純薬工業社製、99%)
ホスホセリン(SIGMA社製、98%)
アセチルセリン(和光純薬工業社製、99%)
リゾホスファチジルセリン(フナコシ社製、98%、牛脳由来)
L-システイン(和光純薬工業社製、99%)
ホスファチジン酸(フナコシ社製、98%、大豆由来)
グリシン(和光純薬工業社製、99%)
行動観察:投与から10分後、各ニワトリヒナを群飼育ケージから行動観察用分離飼育ケージに移した脳室投与の直後に単離ストレス状況下で10分間の行動観察を行い、鳴声と自発運動量の測定を行った。ニワトリヒナの鳴き回数と自発運動量を記録した。10分間の経過と10分間の総数を1羽当たりの平均としてグラフを図10〜21に示した。
試料投与確認観察:麻酔後に断頭し、脳を観察して試薬が側脳室に正しく注入されているか観察した。
(1)Control群
(2)L-セリン(L-Serine(Ser.))投与群
(3)ホスホセリン(Phospho-Serine(Phos-S))投与群
(4)アセチルセリン(Acetyl-Serine(Ace-S))投与群
(5)ホモセリン(Homo- Serine(HS))投与群
(2)L-セリン(L-Serine(Ser.))投与群
(3)ホスホセリン(Phospho-Serine(Phos-S))投与群
(4)アセチルセリン(Acetyl-Serine(Ace-S))投与群
(5)L-システイン(L-Cysteine)投与群
(2)L-セリン(L-Serine(Ser.))投与群
(3)グリシン(Glycine)投与群
(4)ホスファチジン酸(Phosphatidic Acid(PA))投与群
(5)リゾホスファチジルセリン(Lyso Phosphatidyl Serine(Lyso-PS) )投与群
抗不安効果を持つセリンとホスファチジルセリンを含有することを特徴とする健康食品用ソフトカプセル剤の製造
セリン、ホスファチジルセリン25%含有液体大豆レシチン、ビタミンEオイル、ビタミンB1(チアミン硝酸塩)、ビタミンB6(ピリドキシン塩酸塩)、ビタミンB12(シアノコバラミン)、ミツロウとパーム油は表1に示した様な配合量となるように混合し、30分間撹拌した。80メッシュで篩過した後、真空撹拌機で脱泡処理を行った。ソフトカプセル充填機により内容量が250mgとなるように充填した。皮膜は通常用いられるゼラチン、グリセリン混合物を用いた。乾燥後、液漏れ検査、形状選別検査、目視検査を合格した粒について規格試験を行った結果、カプセル長径、カプセル短径、カプセル総重量、カプセル皮膜重量、カプセル内容物重量、皮膜水分含有量、崩壊時間、酸価、過酸化物価、一般生菌数、大腸菌群等の諸規格を満たす製剤であることが確認された。
抗不安効果を持つセリンを含有することを特徴とする健康食品用飲料の製造
セリン、クエン酸、マルチトール、エリスリトール、トレハロース、オレンジ果汁、ラカンカエキス、香料は表1に示した様な配合量で配合し、最後に水を50mlになるように加え、原料を水に混合・溶解させ、容器に充填を行い、85℃10分の殺菌を行った。殺菌後冷却し、本飲料を完成させた。処方例1及び2を表1に、処方例3及び4を表2に示す。
Claims (3)
- セリン、ホスホセリン、アセチルセリンから選択される物質を有効成分とすることを特徴とする抗不安剤。
- ホスホセリン又はアセチルセリンが蛋白質加水分解法、化学合成法、酵素法、又は動物、植物などから抽出・精製のいずれかの方法によって製造されたものであることを特徴とする請求項1記載の抗不安剤。
- セリン、ホスホセリン、アセチルセリンの含有量が5質量%以上であることを特徴とする請求項1又は2に記載の抗不安剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005029114A JP4878436B2 (ja) | 2004-02-04 | 2005-02-04 | 抗不安剤 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004028405 | 2004-02-04 | ||
JP2004028405 | 2004-02-04 | ||
JP2005029114A JP4878436B2 (ja) | 2004-02-04 | 2005-02-04 | 抗不安剤 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011124709A Division JP5351930B2 (ja) | 2004-02-04 | 2011-06-03 | 抗不安剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005247841A JP2005247841A (ja) | 2005-09-15 |
JP4878436B2 true JP4878436B2 (ja) | 2012-02-15 |
Family
ID=35028667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005029114A Active JP4878436B2 (ja) | 2004-02-04 | 2005-02-04 | 抗不安剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4878436B2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018188413A (ja) * | 2017-05-09 | 2018-11-29 | 株式会社ファンケル | 皮膚外用剤 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8003683B2 (en) | 2005-11-11 | 2011-08-23 | Signature R&D Holdings, Llc | Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements |
JPWO2007060924A1 (ja) * | 2005-11-22 | 2009-05-07 | 味の素株式会社 | 膵β細胞保護剤 |
US7902401B2 (en) | 2006-12-14 | 2011-03-08 | Nps Pharmaceuticals, Inc. | Fluorinated compounds |
US9517221B2 (en) | 2006-03-09 | 2016-12-13 | Ono Pharmaceutical Co., Ltd. | (2R)-2-propyloctanoic acid for functional brain disease |
WO2008013215A1 (fr) * | 2006-07-28 | 2008-01-31 | Fancl Corporation | Préparation orale induisant le sommeil, et préparation orale pour soigner l'insomnie liée au stress |
WO2008070994A1 (en) * | 2006-12-14 | 2008-06-19 | Nps Pharmaceuticals, Inc. | Use of d-serine derivatives for the treatment of anxiety disorders |
JP2010195752A (ja) * | 2009-02-27 | 2010-09-09 | Unitika Ltd | 骨形成促進剤 |
JP2011016728A (ja) * | 2009-07-07 | 2011-01-27 | Yamaguchi Univ | 炎症性疾患の予防剤および/または治療剤 |
JP6313626B2 (ja) * | 2014-03-28 | 2018-04-18 | 株式会社ファンケル | 顆粒剤 |
JP6693413B2 (ja) * | 2014-04-30 | 2020-05-13 | 味の素株式会社 | 消化管障害を改善する組成物 |
JP2015044872A (ja) * | 2014-12-08 | 2015-03-12 | ユニチカ株式会社 | 生体コラーゲン合成促進剤 |
CN114544821B (zh) * | 2020-11-24 | 2023-10-24 | 重庆医科大学 | 检测血浆中磷脂酰乙醇胺(36:4)的试剂在制备抑郁症检测试剂盒中的用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040234544A1 (en) * | 2001-08-09 | 2004-11-25 | Ralf Jager | Formulation containing (lyso-)phosphatidylserine for the prevention and treatment of stress states in warm blooded animals |
-
2005
- 2005-02-04 JP JP2005029114A patent/JP4878436B2/ja active Active
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018188413A (ja) * | 2017-05-09 | 2018-11-29 | 株式会社ファンケル | 皮膚外用剤 |
JP2021011504A (ja) * | 2017-05-09 | 2021-02-04 | 株式会社ファンケル | 皮膚外用剤 |
JP7111789B2 (ja) | 2017-05-09 | 2022-08-02 | 株式会社ファンケル | 皮膚外用剤 |
Also Published As
Publication number | Publication date |
---|---|
JP2005247841A (ja) | 2005-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4878436B2 (ja) | 抗不安剤 | |
JP6016363B2 (ja) | 脳神経細胞新生剤 | |
JP3195594B2 (ja) | 乳由来のリン脂質を配合した食品組成物。 | |
ES2325260T3 (es) | Utilizacion de esfingolipidos para reducir los niveles de triacilglicerol y colesterol en el plasma. | |
Burling et al. | Milk–A new source for bioactive phospholipids for use in food formulations | |
JP3999249B2 (ja) | 睡眠誘導剤、ストレス性不眠症改善剤 | |
JPS6284028A (ja) | 膜流動化のための脂質混合物 | |
JP6150735B2 (ja) | 神経再生剤 | |
JP6669761B2 (ja) | 不安神経症を治療するための中鎖脂肪酸及びそれらのトリグリセリド | |
EP3082796B1 (en) | Efficacy of dietary dha-phospholipid for brain dha and dpa accretion in neonates | |
US3819480A (en) | Composition of methionine with 2-dimethylaminoethanol | |
WO2008013215A1 (fr) | Préparation orale induisant le sommeil, et préparation orale pour soigner l'insomnie liée au stress | |
JP2008056628A (ja) | 睡眠誘導剤、ストレス性不眠症改善剤 | |
JP5351930B2 (ja) | 抗不安剤 | |
JPH01135720A (ja) | 神経線維再生剤 | |
CN101112393A (zh) | 一种表面活性物质组合物莫尔尤菲及其制备方法与用途 | |
CN100430046C (zh) | 用于治疗与年龄相关的疾病的组合物与方法 | |
JP2007230954A (ja) | 睡眠誘導剤及びストレス性不眠症改善剤 | |
JP2012518641A (ja) | 脂肪腫および脂肪肉腫を治療する方法 | |
JP2021078397A (ja) | 脂質減少促進剤 | |
TWI745609B (zh) | 具抗氧化活性之組合物 | |
JP2007145814A (ja) | 血小板活性化因子受容体拮抗剤および組成物 | |
JP5110683B2 (ja) | 睡眠誘導剤、ストレス性不眠症改善剤 | |
Gustafson et al. | WILD ALASKAN BLUEBERRY EXTRACTS INHIBIT A MAGNESIUM-DEPENDENT NEUTRAL SPHINGOMYELINASE ACTIVITY IN NEURONS EXPOSED TO TNFɑ. | |
WO2019146652A1 (ja) | 抗i型アレルギー剤、及び肥満細胞又は好塩基球の脱顆粒抑制剤、並びに抗認知症剤、及び短期記憶障害改善/抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080107 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110419 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110603 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110628 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110912 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20111003 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111122 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111128 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4878436 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141209 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141209 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |